Edgar Filing: ENANTA PHARMACEUTICALS INC - Form DEFA14A

ENANTA PHARMACEUTICALS INC Form DEFA14A January 19, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to § 240.14a-12

ENANTA PHARMACEUTICALS, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of filing fee (Check the appropriate box):

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form DEFA14A

No fee required.
Fee computed on table below per Exchange Act Rules 14a-(6) (i) (1) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transactions applies:
(2) Paramit arise on other and other relations when of the acception commuted assessment to Euchemen Act Puls () 11 (cot
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
(b) Total lee paid.
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for
which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing:
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(2) Torm, belieduic of Registration Statement 110
(3) Filing Party:

(4) Date Filed:

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on February 28, 2018 for Enanta Pharmaceuticals, Inc.

This communication is not a form of voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement, annual report, directions to the annual meeting and voting instructions, go to www.proxydocs.com/enta. To submit your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. We have chosen to use these procedures for our 2018 Annual Meeting and need YOUR participation.

If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year s Annual Meeting, please make this request on or before February 18, 2018.

For a Convenient Way to VIEW Proxy Materials and
VOTE Online go to: www.proxydocs.com/enta
Proxy Materials Available to View or Receive:

Annual Report and Proxy Statement

Printed materials may be requested by one of the following methods:

INTERNET TELEPHONE *E-MAIL

www.investorelections.com/enta (866) 648-8133

paper@investorelections.com

* If requesting material by e-mail, please send a blank e-mail with

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form DEFA14A

You must use the 12 digit control number

located in the shaded gray box below.

the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material.

Enanta Pharmaceuticals, Inc. Notice of Annual Meeting

Meeting Type: Annual Meeting

Date: Wednesday, February 28, 2018 Time: 4:00 P.M. (Eastern Time)

Place: Residence Inn by Marriott Boston Watertown, 570 Arsenal

Street, Watertown, MA 02472

The purpose of this Annual Meeting is to take action on the following proposals:

The Board of Directors recommends a vote FOR each of the director nominees listed in proposal 1 and FOR proposal 2.

1. To elect three Class II directors to serve until the 2021 Annual Meeting of Stockholders or until their respective successors are elected and qualified.

Nominees: (01) George S. Golumbeski

- (02) Kristine Peterson
- (03) Terry C. Vance
- 2. To ratify the appointment of PricewaterhouseCoopers LLP as Enanta s independent registered public accounting firm for the 2018 fiscal year.
- 3. To transact any other business that may properly come before the meeting or any adjournment of the meeting. **Vote In-Person Instructions:** While we encourage stockholders to vote online by the means indicated above, a stockholder is entitled to vote in person at the Annual Meeting. If you wish to vote your shares at the Annual Meeting, please register with the Inspector of Elections at the desk marked Stockholder Registration at the entrance to receive a ballot. Proper photo ID is required. Ballots should be returned to the Inspector of Elections in order to be counted. Additionally, a stockholder who has submitted a proxy before the meeting may revoke that proxy in person at the Annual Meeting.